07:00 , Jul 9, 2012 |  BioCentury  |  Strategy

Triple play in diabetes

The addition of Amylin Pharmaceuticals Inc. 's glucagon-like peptide 1 franchise will give partners Bristol-Myers Squibb Co. and AstraZeneca plc three modern mechanisms in their commercial diabetes portfolio and five in the pipeline - more...
08:00 , Feb 13, 2012 |  BC Week In Review  |  Clinical News

AC165198: Phase I started

Amylin disclosed in its 4Q11 earnings that in January it began a Phase I trial to evaluate AC165198. Amylin and Biocon are jointly developing and commercializing AC165198 under a 2009 deal (see BioCentury, Sept. 14,...